[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 63.00 61.00 65.00 63.00 63.00 63.00 10,919 08:00:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.7 -9.2 -5.4 - 173

Redx Pharma Share Discussion Threads

Showing 376 to 397 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
31/12/2019
10:08
Clearly the market has low expectations
shaker44
31/12/2019
09:46
I think it will be in the 16 to 18 pence a share
naplion
31/12/2019
09:12
Comment by from another persons: If an offer is forthcoming, the valuation is going to be very interesting - not just the value they attribute to the pan-RAF inhibitor licensed to Jazz Pharmaceuticals but more importantly to the Porcupine Inhibitors, especially RXC004 as the only clinical stage candidate. Market cap was sitting around £8m this morning and worth remembering that Redx have already sold one drug for $40m and that was pre-clinical and at fire sale prices. That drug has since gone on to produce some fantastic early clinical trial results and now has pride of place in Eli Lilly's oncology pipeline - a fact that won't be lost on anyone looking at Redx today.
shovon1000
31/12/2019
08:29
Yes, price tag will be around 12/14
shovon1000
31/12/2019
08:25
MGL has played this expertly
matt123d
31/12/2019
08:22
the Company confirms that it is in discussions with Samuel D. Waksal and associates (the "Bidder") in relation to a possible cash offer to be made by an investment syndicate led by the Bidder for the entire issued, and to be issued, share capital of Redx.
shovon1000
31/12/2019
08:15
Yes possible offer of around 12/14 pence
shovon1000
31/12/2019
08:10
An offer in the 12-13p area probably. Picked a few up first thing.
matt123d
16/12/2019
10:44
Following on from my previous Open Orphans (ORPH) posts, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform. At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020
sunningdale1
02/12/2019
08:21
For those interested in my previous post on Open Orphan (ORPH), November delivered some big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year. CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/ This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen. Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.
sunningdale1
03/11/2019
09:39
Some volume on Friday, makes a change...
soulected
18/10/2019
08:00
All gone a little bit quiet here and share price falling. I wonder when the trial for the second patient cohort / those receiving the higher pre-specified dose of RXC004 will begin? Anson commented results will be released in 2020. Hopefully will see some other news before then to stop this going down. In the meantime, for those interested in Pharma stocks Open Orphan AIM:ORPH is one I’d recommend keeping an eye on (shameless plug) - CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year The company has a four pronged strategy including a European health data collection platform - with patient clinical and genomic data. For measure GSK recently valued an Alzheimers neurologival disorder database for £300m so big money business. CCO Maurice Treacy explains on proactive https://www.youtube.com/watch?v=eFvPcwjL-m4
sunningdale1
14/10/2019
12:08
3% drop on a £1750 sell!
soulected
07/8/2019
12:46
Not surprised it moves on so little buying. Been a buy order in the system this week, see how much stock it took to drop this compared with what it takes to spike it
dave4545
01/8/2019
17:53
Starting to look good, mm's has been buying all stock up for days clearly for a order, then any buy seems to move the price. Heading back to 12-14p range soon enough
dave4545
30/7/2019
13:51
Had to happen, that 100k buyer has took size out of a illiquid market.
dave4545
30/7/2019
13:18
Good call there dave4545.
noirua
30/7/2019
10:55
Another 100k buy at 10.5p Not many people would buy 100k at 10.5p when monitor spread is 8.5-10.5p The mm's are desperate to kill this in the hope others sell through boredom or lack of movement. That 100k buyer needs around a 25% movement just to break even so they clearly see more medium term potential to risk buying on that spread
dave4545
29/7/2019
09:50
Idiot of the week sells on a shake at 8.71p when others are paying 9.8p
dave4545
26/7/2019
09:34
Just added some at 9.4p, all buys and price to buy increasing so I see movement later on if this continues.
dave4545
22/7/2019
21:39
Nice 100k buy there at 10.2p Nice bounce today as expected.
dave4545
22/7/2019
11:37
Overhang from spike has cleared, nearly all traders have moved on meaning little left to be sold. So I see this getting back to 11-13p range, 9.5p full offer just been paid
dave4545
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
REDX
Redx Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211208 19:47:13